

# CITATION REPORT

List of articles citing

## Ganglioside GM2 as a human tumor antigen (OFA-I-1)

DOI: 10.1073/pnas.80.17.5392

Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 5392-6.

**Source:** <https://exaly.com/paper-pdf/16573869/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
161	Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice. <b>1984</b> , 8, 169-74		23
160	Human Monoclonal Antibody Against Ganglioside GD2: Use in Development of Enzyme-Linked Immunosorbent Assay for the Monitoring of Anti-GD2 in Cancer Patients2. <b>1984</b> ,		
159	Biochemical study on gangliosides in neurofibromas and neurofibrosarcomas of Recklinghausen@ disease. <b>1984</b> , 11, 129-38		13
158	Glycosphingolipids * *Sialic acid-containing glycosphingolipids (the gangliosides) are discussed in a separate chapter (see Chapter 3).. <b>1985</b> , 10, 1-99		29
157	Human cancer-associated antigens: present status and implications for immunodiagnosis. <i>Advances in Cancer Research</i> , <b>1985</b> , 44, 1-42	5.9	39
156	A new breast carcinoma antigen defined by a monoclonal antibody. <b>1985</b> , 75, 801-11		59
155	Carbohydrate structure in tumor immunity. <b>1985</b> , 4, 221-60		49
154	Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. <b>1985</b> , 314, 53-7		1163
153	Immunogenicity of melanoma-associated gangliosides in cancer patients. <b>1985</b> , 35, 607-12		145
152	Gangliosides. <b>1985</b> , 199-260		136
151	A monoclonal antibody reacting specifically with ganglioside GD1b in human brain. <b>1985</b> , 189, 23-6		19
150	GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. <b>1986</b> , 208, 17-22		66
149	Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1986</b> , 83, 8694-8	11.5	182
148	Regulation of GM2 ganglioside metabolism in cultured cells. <b>1986</b> , 42, 105-16		5
147	Production of oligosaccharide-binding monoclonal antibodies of diverse specificities by immunization with purified tumor-associated glycolipids inserted into liposomes with lipid A. <b>1986</b> , 16, 951-6		26
146	Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>1986</b> , 22, 221-31	7.4	23
145	A hypothesis on the biological role of ABH, lewis and P blood group determinant structures in glycosphingolipids and glycoproteins. <b>1986</b> , 3, 95-108		45

144	Tumor-associated glycolipid antigens, their metabolism and organization. <b>1986</b> , 42, 209-33		157
143	Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. <b>1986</b> , 102, 688-96		275
142	Human tumor antigens. <b>1987</b> , 40, 323-77		80
141	Cell-surface antigens of melanoma recognized by human monoclonal antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1987</b> , 84, 2416-20	11.5	80
140	Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1987</b> , 84, 2911-5	11.5	188
139	In vitro production of human antibodies specifically reactive with human gastric cancer cells of established lines and autologous tissues. <b>1987</b> , 36, 215-24		4
138	Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. <b>1987</b> , 40, 12-7		49
137	Ganglioside gm2 as a target structure recognized by human natural killer cells. <b>1987</b> , 1, 209-213		4
136	Glycolipid function. <b>1987</b> , 906, 137-60		176
135	Glycosphingolipids and antitumor immunity. <b>1987</b> , 907, 125-43		20
134	Mouse monoclonal antibodies detecting disialogangliosides on mouse and human T lymphomas. <b>1988</b> , 41, 267-74		22
133	Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. <b>1988</b> , 41, 336-43		40
132	Different reactivities of monoclonal antibodies to ganglioside lactones. <b>1988</b> , 958, 134-8		20
131	Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. <b>1988</b> , 540, 64-77		5
130	Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 4441-5	11.5	25
129	Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 3965-9	11.5	28
128	Different fine binding specificities of monoclonal antibodies to disialosylganglioside GD2. <b>1988</b> , 103, 682-7		8
127	Developmental changes of C-series polysialogangliosides in chick brains revealed by mouse monoclonal antibodies M6704 and M7103 with different epitope specificities. <b>1988</b> , 104, 973-9		39

126	Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. <i>Advances in Cancer Research</i> , <b>1989</b> , 52, 257-331	5.9	861
125	Ganglioside GD3 shedding by human malignant melanoma cells. <b>1989</b> , 44, 155-60		58
124	Active specific immunotherapy in malignant melanoma. <b>1989</b> , 5, 420-5		33
123	Human monoclonal antibodies: prospects for the therapy of cancer. <b>1989</b> , 5, 448-52		11
122	Density of GM3 with normal primary structure determines mouse melanoma antigenicity; a new concept of tumor antigen. <b>1989</b> , 80, 988-92		15
121	A human monoclonal antibody recognizing a surface antigen on stomach cancer cells. <b>1989</b> , 80, 546-53		5
120	Insulin pen injectors. <b>1989</b> , 1, 787		4
119	Interaction of Clostridium perfringens delta toxin with erythrocyte and liposome membranes and relation with the specific binding to the ganglioside GM2. <b>1989</b> , 27, 1113-26		21
118	Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. <b>1989</b> , 43, 857-62		24
117	Human monoclonal antibody to ganglioside GM2 for melanoma treatment. <b>1989</b> , 1, 786-7		69
116	Strong anti-tumor effect of monosialoganglioside specific monoclonal antibody 202: a clinical trial in a cancer patient with melanoma. <b>1989</b> , 16, 480-6		5
115	Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 3333-7 <sup>11.5</sup>		38
114	Alloimmunization with cultured human stomach cancer cell lines and the establishment of human-human hybridomas producing monoclonal antibodies. <b>1990</b> , 81, 967-70		11
113	Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone. <b>1990</b> , 81, 383-7		7
112	Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , <b>1990</b> , 32, 228-34	7.4	6
111	Molecular changes in carbohydrate antigens associated with cancer. <b>1990</b> , 12, 223-30		135
110	Oligosaccharide Y specific monoclonal antibody and its isotype switch variants. <b>1990</b> , 9, 201-10		24
109	Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. <b>1990</b> , 1043, 267-72		16

108	Epitope- and antigen-specific cancer vaccines. <i>International Reviews of Immunology</i> , <b>1991</b> , 7, 245-57	4.6	9
107	SV-40 transformation: effect on GM2 ganglioside in cultured cell lines. <b>1991</b> , 1084, 94-100		4
106	Immunobiologic Aspects of Head and Neck Cancer: Clinical and Laboratory Correlates. <b>1991</b> , 5, 797-820		30
105	Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. <b>1991</b> , 49, 893-9		41
104	Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. <i>Journal of Clinical Investigation</i> , <b>1991</b> , 88, 186-92	15.9	57
103	Role of gangliosides in active immunotherapy with melanoma vaccine. <i>International Reviews of Immunology</i> , <b>1991</b> , 7, 303-29	4.6	27
102	Melanoma-associated antigen synthesized in vitro for active specific immunotherapy. <b>1992</b> , 19, 823-6		
101	Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. <b>1992</b> , 216, 463-82		313
100	Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. <b>1992</b> , 1117, 97-103		113
99	Cellular and molecular biology of melanoma. <b>1992</b> , 8, 353-7		3
98	Immunotherapy with monoclonal antibodies in metastatic melanoma. <b>1992</b> , 16, 261-9		19
97	Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6). <b>1992</b> , 203, 577-86		23
96	In vitro biosynthesis of GbOse4Cer (globoside) and GM2 ganglioside by the (1-->3) and (1-->4)-N-acetyl beta-D-galactosaminyltransferases from embryonic chicken brain. Solubilization, purification, and characterization of the transferases. <b>1992</b> , 236, 227-44		10
95	Generation of a monoclonal antibody specific for a new class of minor ganglioside antigens, GQ1b alpha and GT1a alpha: its binding to dorsal and lateral horn of human thoracic cord. <b>1993</b> , 623, 83-8		32
94	Tumor antigens known to be immunogenic in man. <b>1993</b> , 690, 50-8		19
93	Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. <b>1993</b> , 690, 120-34		53
92	Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. <i>Journal of Clinical Oncology</i> , <b>1994</b> , 12, 1036-44	2.2	448
91	Generation of monoclonal antibodies specific for ganglioside lactones: evidence of the expression of lactone on human melanoma cells. <b>1994</b> , 58, 263-8		25

90	Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. <b>1994</b> , 169, 257-72		46
89	Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. <b>1994</b> , 101, 225-40		23
88	Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. <b>1994</b> , 101, 251-75		29
87	The role of adjuvant therapy in melanoma management. <i>Cancer</i> , <b>1995</b> , 75, 726-34	6.4	66
86	GM2 ganglioside and pyramidal neuron dendritogenesis. <b>1995</b> , 20, 1287-99		45
85	Peptides with carboxyl-terminal sequence of alanine-proline: detection by a human monoclonal antibody. <b>1995</b> , 14, 45-50		6
84	T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. <b>1995</b> , 14, 209-16		18
83	Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 2805-9 <sup>1.5</sup>		40
82	The chemical constitution of gangliosides of the vertebrate nervous system. <b>1995</b> , 66, 85-97		50
81	Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. <b>1996</b> , 35, 287-95		7
80	Sulfatides as a predictive factor of lymph node metastasis in patients with colorectal adenocarcinoma. <i>Cancer</i> , <b>1996</b> , 78, 43-7	6.4	34
79	Current status of human melanoma vaccines: can they control malignant melanoma?. <i>BioDrugs</i> , <b>1997</b> , 7, 66-84	7.9	3
78	Adjuvant therapy for cutaneous malignant melanoma. <b>1997</b> , 36, 747-64		25
77	Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. <b>1997</b> , 178, 162-71		7
76	Update on active specific immunotherapy with melanoma vaccines. <b>1997</b> , 66, 55-64		15
75	GM2 ganglioside as a regulator of pyramidal neuron dendritogenesis. <b>1998</b> , 845, 188-99		30
74	Cancer-associated glycosphingolipid antigens: their structure, organization, and function. <b>1998</b> , 161, 79-90		125
73	Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. <b>1998</b> , 8, 695-705		32

72	Clinical implications of the new biology in the development of melanoma vaccines. <b>1999</b> , 70, 263-74		12
71	THE MANAGEMENT OF UVEAL MELANOMA IN THE NEXT MILLENNIUM. <b>1999</b> , 12, 493-506		3
70	Human IgM antibody therapy for HIV-1 infection. <b>1999</b> , 43, 729-36		3
69	The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients. <b>2000</b> , 44, 405-10		4
68	Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. <b>2000</b> , 10, 1028-37		67
67	The Role of Natural Products in Drug Discovery. <b>2000</b> ,		1
66	Natural and induced human antibody response to cancer. <i>Cancer Investigation</i> , <b>2000</b> , 18, 480-9	2.1	7
65	Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. <i>Advances in Experimental Medicine and Biology</i> , <b>2001</b> , 491, 369-402	3.6	329
64	Gangliosides: therapeutic agents or therapeutic targets?. <b>2002</b> , 12, 1215-1223		13
63	Partitioning of Ganglioside-Reconstituted Liposomes in Aqueous Two-Phase Systems. <b>2002</b> , 17, 87-104		4
62	Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. <b>2002</b> , 236, 438-48; discussion 448-9		121
61	A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. <i>Molecular Immunology</i> , <b>2002</b> , 39, 103-12	4.3	26
60	Melanoma vaccines. <i>Cancer Investigation</i> , <b>2002</b> , 20, 1012-26	2.1	11
59	Tumor suppressive monoclonal antibody belonging to the VH 7183 family directed to the oncodevelopmental carbohydrate antigen on human hepatocellular carcinoma. <i>Journal of Bioscience and Bioengineering</i> , <b>2002</b> , 93, 266-273	3.3	4
58	Royal College of Radiologists Annual Undergraduate Essay Prize. Melanoma: the new smallpox? Can vaccines be used to treat melanoma?. <i>Clinical Oncology</i> , <b>2002</b> , 14, 17-22	2.8	
57	Immunotherapy of malignant melanoma. <i>Surgical Clinics of North America</i> , <b>2003</b> , 83, 343-70	4	26
56	Ganglioside-based vaccines and anti-idiotypic antibodies for active immunotherapy against cancer. <i>Expert Review of Vaccines</i> , <b>2003</b> , 2, 817-23	5.2	28
55	Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 313-9	2.2	29

54	Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 110-7	7.4	64
53	Therapeutic vaccines for melanoma: current status. <i>BioDrugs</i> , <b>2005</b> , 19, 247-60	7.9	28
52	Vaccine therapy of malignant melanoma. <i>Clinical and Applied Immunology Reviews</i> , <b>2006</b> , 6, 217-230		2
51	Application of carbohydrate array technology to antigen discovery and vaccine development. <i>Expert Review of Vaccines</i> , <b>2007</b> , 6, 957-69	5.2	29
50	Anticarbohydrate Antibodies. <b>2007</b> , 765-785		2
49	Cancer Vaccines: Activating the Immune System to Fight Cancer. <i>Oncology Issues</i> , <b>2008</b> , 23, 18-24	0.2	2
48	Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?. <i>International Reviews of Immunology</i> , <b>2011</b> , 30, 238-93	4.6	4
47	A Multicolor Nanoprobe for Detection and Imaging of Tumor-Related mRNAs in Living Cells. <i>Angewandte Chemie</i> , <b>2012</b> , 124, 7544-7548	3.6	26
46	A multicolor nanoprobe for detection and imaging of tumor-related mRNAs in living cells. <i>Angewandte Chemie - International Edition</i> , <b>2012</b> , 51, 7426-30	16.4	263
45	UVB-irradiated keratinocytes induce melanoma-associated ganglioside GD3 synthase gene in melanocytes via secretion of tumor necrosis factor $\alpha$ and interleukin 6. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 445, 504-10	3.4	15
44	Simple sugars to complex disease--mucin-type O-glycans in cancer. <i>Advances in Cancer Research</i> , <b>2015</b> , 126, 53-135	5.9	119
43	Therapeutic Strategies for Human IgM Antibodies Directed at Tumor-Associated Ganglioside Antigens: Discoveries Made During the Morton Era and Future Directions. <i>Critical Reviews in Oncogenesis</i> , <b>2016</b> , 21, 75-81	1.3	4
42	Inflammatory Reactions in Microenvironments, Leading to Melanomagenesis. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2017</b> , 08,	2.7	1
41	Differential roles of gangliosides in malignant properties of melanomas. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206881	3.7	33
40	DNA Octahedron-Based Fluorescence Nanoprobe for Dual Tumor-Related mRNAs Detection and Imaging. <i>Analytical Chemistry</i> , <b>2018</b> , 90, 12059-12066	7.8	46
39	Target induced reconstruction of DNAzymatic amplifier nanomachines in living cells for concurrent imaging and gene silencing. <i>Chemical Communications</i> , <b>2018</b> , 54, 10626-10629	5.8	15
38	The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. <i>Nature Reviews Drug Discovery</i> , <b>2021</b> , 20, 217-243	64.1	60
37	The role of adjuvant therapy in melanoma management. <i>Cancer</i> , <b>1995</b> , 75, 726-734	6.4	57



36	Gangliosides as Targets for Monoclonal Antibody Therapy of Cancer. <b>1990</b> , 75-94		6
35	Gangliosides as antigens of human melanoma. <i>Cancer Treatment and Research</i> , <b>1988</b> , 43, 17-43	3.5	11
34	Neuron-Reactive Antibodies in Systemic Lupus Erythematosus. <b>1985</b> , 237-249		1
33	A guide to monoclonal antibodies directed to glycotopes. <i>Advances in Experimental Medicine and Biology</i> , <b>2001</b> , 491, 587-630	3.6	27
32	Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma. <i>Cancer Treatment and Research</i> , <b>1991</b> , 54, 137-51	3.5	18
31	Present status of the immunology of gangliosides. <i>Advances in Experimental Medicine and Biology</i> , <b>1984</b> , 174, 15-25	3.6	11
30	Monoclonal Antibodies Directed to Cell-Surface Carbohydrates. <b>1984</b> , 67-100		18
29	Melanoma Antigens. <b>2002</b> , 157-182		1
28	Chemical Biology and Biomedicine: Glycolipids and Glycosphingolipids. <b>2001</b> , 2183-2249		5
27	Gangliosides in Melanoma. <b>1990</b> , 15-30		16
26	ANTIBODIES TO TUMOR-ASSOCIATED GANGLIOSIDES (GM2 AND GD2): POTENTIAL FOR SUPPRESSION OF MELANOMA RECURRENCE. <b>1985</b> , 371-384		2
25	Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3.. <i>Journal of Biological Chemistry</i> , <b>1985</b> , 260, 14556-14563	5.4	95
24	Monoclonal antibodies against the human epidermal growth factor receptor from A431 cells. Isolation, characterization, and use in the purification of active epidermal growth factor receptor.. <i>Journal of Biological Chemistry</i> , <b>1984</b> , 259, 9906-9912	5.4	66
23	Monoclonal antibody detects monosialogangliosides having a sialic acid alpha 2B-galactosyl residue.. <i>Journal of Biological Chemistry</i> , <b>1987</b> , 262, 6803-6807	5.4	25
22	A New Ganglioside of the Lactotetraose Series, GalNAc-3?-isoLM1, Detected in Human Meconium. <i>Journal of Biological Chemistry</i> , <b>1989</b> , 264, 12122-12125	5.4	15
21	Aberrant fatty acyl Hydroxylation in human neuroblastoma tumor gangliosides. <i>Journal of Biological Chemistry</i> , <b>1989</b> , 264, 12097-12105	5.4	59
20	Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies.. <i>Journal of Biological Chemistry</i> , <b>1988</b> , 263, 18507-18512	5.4	35
19	Pathogenic cascades and brain dysfunction. <b>2004</b> , 290-324		15

18	The CLIMB (Complex Lipids In Mothers and Babies) study: protocol for a multicentre, three-group, parallel randomised controlled trial to investigate the effect of supplementation of complex lipids in pregnancy, on maternal ganglioside status and subsequent cognitive outcomes in the offspring. <i>BMJ Open</i> , <b>2017</b> , <i>7</i> , e016637	3	13
17	Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. <i>Journal of Clinical Investigation</i> , <b>1985</b> , <i>76</i> , 849-54	15.9	21
16	Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody. <i>Journal of Clinical Investigation</i> , <b>1988</b> , <i>81</i> , 1746-51	15.9	12
15	Review of melanoma antigens recognized by monoclonal antibodies (MAbs). Their functional significance and applications in diagnosis and treatment of melanoma. <i>Pathology</i> , <b>1985</b> , <i>17</i> , 346-54	1.6	16
14	New directions in immunopharmacotherapy. <i>Ernst Schering Research Foundation Workshop</i> , <b>2000</b> , 315-46		
13	Secondary Neuroprotection. <b>2003</b> , 285-351		
12	Cancer vaccines. <b>2003</b> , 163-182		
11	Cancer vaccines. <b>2009</b> , 147-153		
10	Monoclonal Antibodies Against Gangliosides. <b>1987</b> , 423-433		2
9	Tumorantigene bei menschlichen Tumoren. <b>1987</b> , 23-57		
8	Ganglioside content and composition in human gliomas. <b>1988</b> , <i>43</i> , 126-9		3
7	Binding sites of monoclonal anti-carbohydrate antibodies. <i>Current Topics in Microbiology and Immunology</i> , <b>1988</b> , <i>139</i> , 59-79	3.3	8
6	Monoclonal Antibodies as Immunomodulating Agents in the Treatment of Melanoma. <b>1990</b> , 387-395		
5	Tumormarker. <i>Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin</i> , <b>1991</b> , 403-465		
4	Glycosphingolipids: Diagnostic and Therapeutic Relevance in Human Gliomas. <b>1998</b> , 291-297		
3	Cellular immuno-PCR. Detection of a carbohydrate tumor marker. <i>American Journal of Pathology</i> , <b>1998</b> , <i>152</i> , 1427-32	5.8	16
2	Active Specific Immunotherapy in the Treatment of Patients with Cancer. <i>Immunology and Allergy Clinics of North America</i> , <b>1991</b> , <i>11</i> , 401-423	3.3	1
1	Complement-Mediated Anti-HIV-1 Effect Induced by Human IgM Monoclonal Antibody Against Ganglioside GM2. <b>1999</b> , <i>162</i> , 533-539		1

